Vimarsana
Biggest News Aggregation in the World

Page 3 - Dan Forche News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dan Forche. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dan Forche Today - Breaking & Trending Today

PreludeDx™ DCISionRT® Data Presented in Spotlight Presentation at the 2022 San Antonio Breast Cancer Symposium - Vimarsana News

PreludeDx™ DCISionRT® Data Presented in Spotlight Presentation at the 2022 San Antonio Breast Cancer Symposium

Published: December 9, 2022

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study...

Source: prnewswire.com
Related Topics:
United StatesDan ForcheAndrew WadeRachel RabinovitchCory DunnRisk Group Not ClinicallyPrnewswire Prelude Corporation PreludedxNational Cancer InstitutePrelude CorporationUniversity Of California San FranciscoAntonio Breast Cancer SymposiumBreast Ductal CarcinomaSitu Patients ComparedClinicopathologic CriteriaLow Risk Group Not Clinically BenefitingLow RiskRadiation OncologyCalifornia San FranciscoKnow YourFjord VenturesDecision ScoreKnow Your RiskHealth Care Amp HospitalsMedical Pharmaceuticals Trade Show News
PreludeDx™ Announces Latest Data on DCISionRT® in Multiple Presentations at the 2022 San Antonio Breast Cancer Symposium - Vimarsana News

PreludeDx™ Announces Latest Data on DCISionRT® in Multiple Presentations at the 2022 San Antonio Breast Cancer Symposium

Published: November 16, 2022

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...

Source: prnewswire.com
Related Topics:
Western AustraliaUnited StatesSan AntonioPat WhitworthDan ForcheAndrew WadeRachel RabinovitchCory DunnYvonne Zissiadis JrFrank ViciniRisk Group Not ClinicallyPrnewswire Prelude Corporation PreludedxNational Cancer InstituteNashville Breast CenterUniversity Of TennesseePrelude CorporationUniversity Of California San FranciscoHenryb Gonzalez Convention CenterAntonio Breast Cancer SymposiumConvention CenterPredict RegistryBreast Ductal CarcinomaSitu Patients ComparedClinicopathologic CriteriaLow Risk Group Not Clinically Benefiting
GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT - Vimarsana News

GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT

Published: October 31, 2022

/PRNewswire/ -- GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx(TM)), a leader in molecular diagnostics...

Source: prnewswire.com
Related Topics:
United StatesNew South WalesUnited KingdomUniversity Of California San FranciscoDan ForcheBruce MannPrnewswire GenesiscareYvonne ZissiadisTroy BremerTherapeutic Goods AssociationNational Cancer InstitutePrelude Corporation PreludedxPrelude CorporationAustralasian International Breast CongressBreast Cancer Network AustraliaBreast Cancer Services For Royal MelbourneDuctal Carcinoma In SituInterim AnalysisTreatment RecommendationBiologic Signature PredictiveRadiation TherapySpecialist Breast SurgeonBreast Cancer ServicesRoyal MelbourneRoyal Women
GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT - Vimarsana News

GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT

Published: October 30, 2022

/PRNewswire/ -- GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx(TM)), a leader in molecular diagnostics...

Source: prnewswire.com
Related Topics:
United StatesNew South WalesUnited KingdomUniversity Of California San FranciscoDan ForcheBruce MannPrnewswire GenesiscareYvonne ZissiadisTroy BremerTherapeutic Goods AssociationNational Cancer InstitutePrelude Corporation PreludedxPrelude CorporationAustralasian International Breast CongressBreast Cancer Network AustraliaBreast Cancer Services For Royal MelbourneDuctal Carcinoma In SituInterim AnalysisTreatment RecommendationBiologic Signature PredictiveRadiation TherapySpecialist Breast SurgeonBreast Cancer ServicesRoyal MelbourneRoyal Women
PreludeDx™ Presents DCISionRT® Data in Oral Presentation at the American Society for Radiation Oncology Annual Meeting - Vimarsana News

PreludeDx™ Presents DCISionRT® Data in Oral Presentation at the American Society for Radiation Oncology Annual Meeting

Published: October 25, 2022

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study...

Source: prnewswire.com
Related Topics:
United StatesSan AntonioChirag ShahDan ForcheAndrew WadeCory DunnPrnewswire Prelude Corporation PreludedxNational Cancer InstitutePrelude CorporationAmerican Society For Radiation OncologyTaussig Cancer InstituteClinical ResearchBreast ProgramUniversity Of California San FranciscoHenryb Gonzalez Convention CenterDepartment Of Radiation OncologyLow Risk ClinicopathologyResidual Risk Groups Who Benefit GreatlyAnnual American SocietyRadiation OncologyConvention CenterLow RiskComprehensive Breast ProgramCleveland ClinicRed Journal